Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.

Nick Colangelo, President and CEO will present at the CG MedTech, Diagnostics, and Digital Health & Service Forum at 10:00 a.m. ET on Thursday, November 17, 2022. Joe Mara, CFO will also present on Thursday, November 17, 2022 at 11:00 a.m. ET at the Stephens Annual Investment Conference.

Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact:
Julie Downs
media@vcel.com

Staff

Recent Posts

Ascentiz Unveiled Modular Designed Exoskeleton at CES 2026: A Technical Deep Dive into Biomechanical Intelligence

The world's first modular exoskeleton combines quasi-direct-drive hip and cable-drive knee technologies for natural, powerful…

6 hours ago

From Clinical Recovery to Lifelong Empowerment: RoboCT Showcases Integrated Ecosystem Strategy at CES 2026

Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral 'New…

6 hours ago

Nanodropper® Now Operating as Mu Medical™, Planned Expansion of Precision Eyecare Platform with Bedo Solutions and Viseon Labs

The consolidated entity will leverage AI and precision engineering to create a comprehensive ecosystem advancing…

6 hours ago

Flo Health’s App Wins Google Play “Best of 2025” Award for Best for Watches in Hong Kong, Taiwan, and Macau

LONDON, Jan. 9, 2026 /PRNewswire/ -- Flo Health, the company behind the globally trusted Flo…

6 hours ago

Gifthealth Celebrates Grand Opening Of New Pharmacy In Mesa

MESA, Ariz., Jan. 9, 2026 /PRNewswire/ -- Gifthealth, a unified digital pharmacy platform, today celebrated the…

6 hours ago

Lucent Health Names Aadam Hussain as Chief Executive Officer Following Brett Rodewald’s Retirement

NASHVILLE, Tenn., Jan. 9, 2026 /PRNewswire/ -- Today, Lucent Health, one of the nation's largest independent…

6 hours ago